|
Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain |
Villa G, Hernandez-Pastor LJ, Guix M, Lavernia J, Cuesta M |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Villa G, Hernandez-Pastor LJ, Guix M, Lavernia J, Cuesta M. Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain. Clinical and Translational Oncology 2014: epub Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /economics /therapeutic use; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Dioxoles /economics /therapeutic use; Disease Progression; Drug Costs; Humans; Probability; Pyrimidines /economics /therapeutic use; Quality-Adjusted Life Years; Sarcoma /drug therapy /economics; Spain; Sulfonamides /economics /therapeutic use; Tetrahydroisoquinolines /economics /therapeutic use; Treatment Outcome AccessionNumber 22014027837 Date bibliographic record published 30/10/2014 |
|
|
|